TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05880290

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: gynaecological examination in lateral decubitus
Description: Single group: gynaecological examination in lateral decubitus, conventional repositioning if unsuccessful
Study: NCT04672954

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to 10 mg BI 474121 administered as uncoated tablets with 240 milliliter of water after subjects fasted overnight for at least 10 hours. This arm was part of Part 1: randomised, placebo-controlled, single-blind.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2.5 milligram (mg) BI 474121
Description: 2.5 mg BI 474121 administered as uncoated tablets (1 x 2.5 mg) with 240 milliliter of water after subjects fasted overnight for at least 10 hours. This arm was part of Part 3 of the study: randomised, open-label.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 milligram (mg) BI 474121
Description: 10 mg BI 474121 administered as uncoated tablets (1 x 10 mg) with 240 milliliter of water after subjects fasted overnight for at least 10 hours. This arm was part of Part 3 of the study: randomised, open-label.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20 milligram (mg) BI 474121
Description: 20 mg BI 474121 administered as uncoated tablets (2 x 10 mg) with 240 milliliter of water after subjects fasted overnight for at least 10 hours. This arm was part of Part 1 of the study: randomised, placebo-controlled, single-blind.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 40 milligram (mg) BI 474121
Description: 40 mg BI 474121 administered as uncoated tablets (4 x 10 mg) with 240 milliliter of water after subjects fasted overnight for at least 10 hours. This arm was part of Part 2 of the study: non-randomised, open-label.
Study: NCT05624047

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breastfeeding education using hybrid simulation method
Description: In addition to the verbal breastfeeding training given to the pregnant women assigned to the experimental group, breastfeeding training will be given using the hybrid simulation method consisting of a wearable breast model and standard patient practice.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Routine verbal breastfeeding education
Description: Women in this group will receive oral breastfeeding training, which is routinely given in the pregnant education class and consists of one session.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Routine verbal breastfeeding education
Description: Women in this group will receive oral breastfeeding training, which is routinely given in the pregnant education class and consists of one session.
Study: NCT04708171

Intervention type: PROCEDURE
Intervention: Awake mapping under local anesthesia
Description: During an awake craniotomy, the patient is awake and cooperative during the resection of the tumor while the surgeon uses electro(sub)cortical mapping to prevent damage to eloquent areas.

Intervention type: PROCEDURE
Intervention: Asleep mapping under general anesthesia
Description: During asleep mapping under general anesthesia, the surgeon uses electro(sub)cortical mapping with evoked potentials (MEPs, SSEPs or continuous dynamic mapping) to prevent damage to eloquent areas.

Intervention type: PROCEDURE
Intervention: Resection under general anesthesia without mapping
Description: During resection under general anesthesia without mapping, the surgeon does not use any intraoperative stimulation mapping techniques to identify eloquent areas.
Study: NCT05099094

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: BD311
Description: Integration-deficient lentiviral vector (IDLV) expressing VEGFA antibody
Study: NCT05737615

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET Scan
Description: Participants will be imaged up to 4 time points post-injection to allow for biodistribution and dosimetry determination

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hu5B1-TCO
Description: On study day 0, a single slow infusion of hu5B1-TCO will be administered intravenously. Subsequently, either 3 days (n = 3) or 5 days (n = 3) later, a single slow infusion of 64Cu-Tz-SarAr will be administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 64Cu-Tz-SarAr
Description: On study day 0, a single slow infusion of hu5B1-TCO will be administered intravenously. Subsequently, either 3 days (n = 3) or 5 days (n = 3) later, a single slow infusion of 64Cu-Tz-SarAr will be administered intravenously.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pharmacokinetics
Description: All participants receiving 64Cu-Tz-SarAr will have serial blood samples drawn.
Study: NCT05045937

Intervention type: DRUG
Intervention: Ivermectin
Description: Ivermectin treatment of outpatients dosing at 0.4mg/kg until recovered along with supplemental treatment using a multi-modal approach.
Study: NCT05210504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-Lysine
Description: 5g L-lysine in 50ml water, administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal Saline
Description: Normal (0.9%) Saline
Study: NCT04583709

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ECG Belt
Description: ECG Belt Research System Procedure LBBP Native conduction RV pacing if available Bipolar LBBP Unipolar LBBP - nonselective and selective (different outputs) Fusion pacing with native conduction at different Atrioventricular (AV) delays~HOT-CRT Native conduction HBP / LBBP HOT-CRT AV delay optimization. Medtronic Device (pacemaker/ICD) based Holter recording during the ECG belt recording
Study: NCT04348968

Intervention type: DEVICE
Intervention: Total hip arthroplasty
Description: The THA surgical procedure involves replacing the head of the femur and acetabulum or socket with an artificial prosthesis. This system is composed of a femoral stem that is inserted into the femoral canal, a ball that attaches to the femoral stem, and an acetabular component or shell that replaces the acetabulum.~In this study, the acetabular component is the Zimmer Maxera Cup, which is a monoblock construct consisting of a pre-assembled shell and liner. The ceramic liner articulates with a ceramic femoral head for a ceramic-on-ceramic large diameter head articulation. The Maxera Cup is intended for single use only and is designed for reconstruction of the hip joint for conditions described in the inclusion and exclusion section of this protocol.
Study: NCT04858178

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Tests of sympathetic inhibition
Description: Bolus phenylephrine infusion using the Oxford technique will generate the need to inhibit sympathetic activity. Similarly, resting state Mayer waves will be assessed with regard to heart rate and blood pressure responses.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Tests of sympathetic inhibition
Description: Bolus phenylephrine infusion using the Oxford technique will generate the need to inhibit sympathetic activity. Similarly, resting state Mayer waves will be assessed with regard to heart rate and blood pressure responses.
Study: NCT06377657

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The HIIT group underwent intervention with high intensity interval training. The second group was treated only with aloe vera supplementation for 12 weeks. A third group underwent a combination of HIIT and supplementation, while a fourth - CON group kept usual activities during the intervention duratino

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The HIIT group underwent intervention with high intensity interval training. The second group was treated only with aloe vera supplementation for 12 weeks. A third group underwent a combination of HIIT and supplementation, while a fourth - CON group kept usual activities during the intervention duratino

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Aloe vera
Description: Aloe Vera group was treated only with aloe vera supplementation for 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Aloe vera
Description: Aloe Vera group was treated only with aloe vera supplementation for 12 weeks.
Study: NCT04858178

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Tests of sympathetic activation
Description: Cold pressor test of the hand will be used to cause sympathetic activation. Valsalva's maneuver will assess the ability to buffer against blood pressure fall (phase II).

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Tests of sympathetic activation
Description: Cold pressor test of the hand will be used to cause sympathetic activation. Valsalva's maneuver will assess the ability to buffer against blood pressure fall (phase II).

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Testing of autonomic dysreflexia
Description: Cold pressor test of the foot and bladder pressor response (in individuals with SCI) will be tested.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous spinal cord stimulation
Description: Transcutaneous spinal cord stimulation will be applied at T7-L1 spinal segments to assess alterations in autonomic neuroregulation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous spinal cord stimulation
Description: Transcutaneous spinal cord stimulation will be applied at T7-L1 spinal segments to assess alterations in autonomic neuroregulation.
Study: NCT05748652

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: digital CBT
Description: An app-based intervention based on principles from cognitive behavioral therapy for anxiety.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Description: Participants will be provided with psychoeducation which will be delivered digitally upon allocation to the psychoeducation arm.
Study: NCT05599568

Intervention type: OTHER
Group type: OTHER
Intervention: Exercise
Description: Either concentric or excentric exercise
Study: NCT05247528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MANP
Description: Novel designer peptide to represent a pGC-A/cGMP therapeutic

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Comparator
Study: NCT06032845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: a PD-1 immune check inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib capsules

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryoablation
Description: Cryoablation is performed under US or CT guidance per Investigator decision.
Study: NCT05293392

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Culturally-Tailored COVID-19 Vaccine Uptake Intervention
Description: This is a multi-component intervention to increase COVID-19 vaccine uptake among youth that was co-created with community partners and refined with qualitative feedback from Black and Latino youth and parents. The intervention consists of culturally-tailored educational materials to increase awareness about the COVID-19 vaccine, culturally-sensitive communication strategies employed by pediatric primary care providers and community health workers, and strategies to facilitate and standardize access to the COVID-19 vaccine in the primary care clinic.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Standard care includes routine offer of the COVID-19 vaccine and counseling about the COVID-19 vaccine by pediatric primary care providers.
Study: NCT04911192

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: mechanical fragmentation
Description: patients who will be treated with catheter-directed mechanical fragmentation under fluoroscopy guidance. This group will include patients with absolute contraindication for fibrinolytic therapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: In Situ thrombolysis
Description: Group (C) will include the patients who will be treated with bed side administration of low dose of local thrombolytic therapy (In Situ) via a trans-Jugular Swan-Ganz pulmonary artery catheter. with guidance of the pressure waveforms obtained from SGC (Swan-Ganz catheter) and echocardiography guidance for ideal Catheter placement. This group will include the patients with relative contraindications for systemic thrombolysis, contraindications for contrasted administration (patients with renal impairment) and also patients with contraindications for radiation exposure (pregnant women).
Study: NCT05864456

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prizvalve Pro™ transcatheter aortic valve system
Description: Transcatheter Aortic Valve Replacement
Study: NCT05402371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rencofilstat
Description: Rencofilstat soft gel capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rencofilstat
Description: Rencofilstat soft gel capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rencofilstat
Description: Rencofilstat soft gel capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo soft gel capsule
Study: NCT05973149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QLH12016
Description: according to the scheme description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QLH12016
Description: according to the scheme description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QLH12016
Description: according to the scheme description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QLH12016
Description: according to the scheme description
Study: NCT05747040

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: monitoring
Description: The intervention consists of 48-h monitoring by using two types of monitoring: an objective monitoring, through a class IIa wearable medical device recording four physiological signals, and a subjective monitoring through a questionnaire developed with Microsoft Forms that can be compiled with a smartphone. The monitoring will be conducted during a motor neurorehabilitation treatment, 24 hours before and 24 hours after the treatment at the participant's home. Besides this monitoring, stratification questionnaires will be administered to each participant to be stratified in one of the three categories (absence of pain, nociceptive pain, or neuropathic pain) based on the following timeline:~t0: baseline t1: pre-treatment t2: post-treatment t3: follow-up
Study: NCT05941403

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Produce Prescription Implementation
Description: Practices make modifications to their usual produce prescription program based on an implementation blueprint. While the exact implementation strategies to be added will be defined based on qualitative data (data collection in progress), possible implementation strategies may include training or technical assistance.
Study: NCT05596877

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music therapy
Description: Performing music therapy during a course of pulmonary rehabilitation (25 mins)
Study: NCT05326659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benvitimod Cream
Description: Benvitimod cream, 1%, applied twice daily for 12 weeks after enrolment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, applied twice daily for 12 weeks after enrolment.
Study: NCT05028361

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: mRNA COVID-19
Description: ACIP-CDC recommended vaccine

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: mRNA COVID-19
Description: ACIP-CDC recommended vaccine

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: IIV4
Description: ACIP recommended vaccine

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: IIV4
Description: ACIP recommended vaccine

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo (saline)
Description: Saline Control

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo (saline)
Description: Saline Control
Study: NCT05814276

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training on non-pharmacological therapies' methodology
Description: The San Rocco study encompasses a training on the non-pharmacological therapies' methodology. It allows the professional caregiver to methodological definition of the non-pharmacological interventions and a comparison of shared readings of the challenging behaviors by the group of colleagues. Participants will follow:~* Five meetings, lasting 11 hours overall, on the multidimensional assessment, the shared readings of behavioral disorders of each person and identification of the objectives through the discussion of cases, and administration of non-pharmacological therapies within the framework of the personalization of the interventions~* Five meetings, lasting five and a half hours, for the supervision of the staff which implement the non-pharmacological therapies.~As usual control group Participants will continue the usual care activities and non-pharmacological interventions already in use in the Nursing Homes without participating in the training.
Study: NCT05647278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegoprazan
Description: Tegoprazan 50 mg, tablets, orally, qd given in combination with amoxicillin 750mg capsules, orally, qid for up to 2 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole
Description: esomeprazole 20 mg, tablets, orally, bid given in combination with amoxicillin 1000mg，clarithromycin 500mg bid，colloidal bismuth pectin 200mg bid for up to 2 weeks.~OR esomeprazole 20 mg, tablets, orally, bis in die given in combination with amoxicillin 750mg capsules, orally, quarter die for up to 2 weeks.
Study: NCT05191056

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo drink
Description: consume 1 bottle per day for 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MelaGene drink
Description: consume 1 bottle per day for 8 weeks
Study: NCT06395493

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pilates Group
Description: In this study, the participants in the Pilates group will undergo 2 sessions per week, for 12 consecutive weeks.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Exercise Group
Description: In this study, the participants in the Exercise group will undergo 2 sessions per week, for 12 consecutive weeks.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Control Group
Description: The participants in the control group, are those who either opt not to do the exercises or are on the waiting list for physiotherapy intervention. Therefore, they will not undergo any intervention for 12 consecutive weeks.
Study: NCT05444712

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy + follow up
Description: * Chemotherapy administrated every 3 weeks for 6 cycles according to local investigator's choice based on usual practices.~* An intermediate evaluation will be performed after four cycles by PET-CT (or CT-Scan for non-avid PTCL)~* A post-induction evaluation by PET-CT or CT-Scan will be done between 3 and 5 weeks after the last chemotherapy drug administration for all patients~* A last evaluation by PET-CT or CT-Scan will be done between 08 and 12 weeks after the post-induction for all patients

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy + ASCT + follow up
Description: * Chemotherapy administrated every 3 weeks for 6 cycles according to local investigator's choice based on usual practices.~* An intermediate evaluation will be performed after four cycles by PET-CT (or CT-Scan for non-avid PTCL)~* The fifth or sixth cycles should be used as stem-cell mobilizing chemotherapy for patients with ASCT strategy~* A post-induction evaluation by PET-CT or CT-Scan will be done between 3 and 5 weeks after the last chemotherapy drug administration for all patients~* Patients with in Complete Response after 6 cycles will receive a High Dose Therapy as conditioning regimen before transplantation~* A last evaluation by PET-CT or CT-Scan will be done between 08 and 12 weeks after the post-induction for all patients
Study: NCT04726332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XL102
Description: oral doses of XL102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XL102
Description: oral doses of XL102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XL102
Description: oral doses of XL102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XL102
Description: oral doses of XL102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XL102
Description: oral doses of XL102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XL102
Description: oral doses of XL102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: fulvestrant 500 mg administered as an intramuscular (IM) injection every 2 weeks for the first 3 doses and then every 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: fulvestrant 500 mg administered as an intramuscular (IM) injection every 2 weeks for the first 3 doses and then every 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone
Description: abiraterone 1000 mg administered orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone
Description: abiraterone 1000 mg administered orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: prednisone 5 mg administered orally twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: prednisone 5 mg administered orally twice daily.
Study: NCT06549803

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: skin bond
Description: In the skin bond group, fascia closure is performed for incision sites of 10 mm or more, and skin bond is sufficiently applied after subcuticular suture.~For incision sites less than 10 mm, subcuticular closure is performed without closing the fascia, and then skin bond is applied.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: skin stapler
Description: In the skin stapler group, fascia closure is performed on incision sites larger than 10 mm, and the skin is closed at 2-3 mm intervals using a stapler.~For incision sites less than 10 mm, skin closure is performed using a skin stapler without closing the fascia.
Study: NCT05242432

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26/protein preF RSV Vaccine
Description: Ad26/protein preF RSV vaccine will be administered as an IM injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26/protein preF RSV Vaccine
Description: Ad26/protein preF RSV vaccine will be administered as an IM injection.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo will be administered as an IM injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo will be administered as an IM injection
Study: NCT05403398

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: B. subtilis CU1
Description: 2 billion CFUs daily, for 4 weeks